Erasca, Inc. announces the pricing of an upsized public offering of 22,500,000 shares of its common stock at $10.00 per share, totaling $225.0 million in gross proceeds. The offering is expected to close on January 23, 2026, with proceeds to fund research, development, and general corporate purposes. Joint book-running managers for the offering are J.P. Morgan, Morgan Stanley, Jefferies, and Evercore ISI. The offering is made under a shelf registration statement on Form S-3 and includes a prospectus supplement filed with the SEC. Erasca is a precision oncology company focused on RAS/MAPK pathway-driven cancers.

Read more at GlobeNewswire: Erasca Announces Pricing of Upsized Public Offering of